 |
|
Related Pages: |
|
|
|
The SELECT Prostate Cancer Prevention Trial
A collection of material about SELECT (Selenium and Vitamin E Cancer Prevention Trial), which will determine whether these two dietary supplements can protect against prostate cancer.
Prostate Cancer Home Page
NCI's gateway for information about prostate cancer.
Prostate Cancer (PDQ®): Prevention
Expert-reviewed information summary about factors that may influence the risk of developing prostate cancer and about research aimed at the prevention of this disease. (Health professional version.)
|
|
|
|
|
|
NCI Materials
The following links will take you to press releases and other materials concerning the Prostate Cancer Prevention Trial that have been prepared by the National Cancer Institute's Office of Communications and Education:
Some Men with Low PSAs Have Prostate Cancer
(Posted: 05/26/2004) - Men with low PSA (prostate specific antigen) levels on screening tests can still have prostate cancer, according to a study released today by scientists from the National Cancer Institute (NCI), part of the National Institutes of Health, and the Southwest Oncology Group, an NCI-funded network of researchers.
First Prostate Cancer Prevention Drug Found, But Not All Men Benefit: NCI Announces Results of Prostate Cancer Prevention Trial
(Posted: 06/24/2003) - Men who took finasteride, a drug that affects male hormone levels, reduced their chances of getting prostate cancer by nearly 25 percent compared to men who took a placebo, according to results of a national study released today online by the New England Journal of Medicine.
Questions and Answers
Se encuentra el primer medicamento para la prevención del cáncer de próstata, aunque no todos los hombres se benefician: El NCI anuncia los resultados del Estudio de Prevención del Cáncer de Próstata (PCPT)
(Publicación: 06/24/2003) - Los hombres que tomaron finasterida, un medicamento que afecta las concentraciones de hormona masculina, redujeron en cerca de un veinticinco por ciento su probabilidad de tener cáncer de próstata, comparados con quienes tomaron placebo, según los resultados de un estudio nacional divulgado hoy en línea por el New England Journal of Medicine.
Prostate Cancer Prevention Trial (PCPT)
(Reviewed: 05/18/2008) - A fact sheet about the Prostate Cancer Prevention Trial (PCPT), which found that 25 percent fewer men taking the drug finasteride developed prostate cancer than men not taking the drug but that men who developed prostate cancer while taking finasteride were more likely to have high-grade cancers.
Estudio de Prevención del Cáncer de Próstata (PCPT)
(Revisión: 06/06/2008) - El Estudio de Prevención del Cáncer de Próstata (PCPT) fue diseñado para ver si el fármaco finasterida podía prevenir contra el cáncer de próstata. 25 por ciento menos hombres de los que tomaron el fármaco presentaron cáncer de próstata en comparación con quienes no lo tomaron. Sin embargo, quienes presentaron cáncer de próstata mientras tomaban finasterida tuvieron más probabilidad de que el cáncer fuera de grado elevado, el cual se puede diseminar rápidamente aunque los tumores sean pequeños. Hoja informativa 4.8s del Instituto Nacional del Cáncer.
Finasteride Not Linked to High-Grade Prostate Cancers
According to two studies in the September 11, 2007, issue of the Journal of the National Cancer Institute, finasteride is unlikely to induce high-grade prostate cancers in men who take the drug to prevent the disease.
Prostate Cancer Risk Calculator Available Online
Researchers have developed an online statistical tool for estimating an individual's risk of developing prostate cancer. The risk calculator is designed to help certain men and their physicians evaluate the potential risks and benefits of being screened for prostate cancer.
Prostate Cancer PSA Testing Limitations Demonstrated
A large-scale study of prostate-specific antigen (PSA) screening for prostate cancer concluded that, contrary to current clinical practice, there is no definitive "cutpoint" PSA level to determine the level of risk for the disease, according to the July 6, 2005, issue of the Journal of the American Medical Association.
NCI Communicates Information on First Prostate Cancer Prevention Trial
An article in the July-August, 2004, issue of Urologic Oncology describes the communication techniques used by NCI to deliver information to the public about the results of the Prostate Cancer Prevention Trial (PCPT).
No "Magic Threshold" for PSA Screening, Study Finds
Data from the National Cancer Institute's (NCI) Prostate Cancer Prevention Trial (PCPT) published recently showed that a substantial number of men enrolled in the trial as controls were found to have prostate cancer despite consistently normal screening tests over the study period. The study results were published in the May 27, 2004, New England Journal of Medicine.
Studies Make Case for Finasteride to Prevent Prostate Cancer
Three new analyses of data from a large prostate cancer prevention trial bolster the case for finasteride as a preventive agent against prostate cancer, according to an article published online May 18, 2008, by the journal Cancer Prevention Research.
< Previous Section | Next Section > |
